Abstract
Cardiotoxicity represents the major side-effect limiting the clinical use of anthracyclines, especially doxorubicin, in cancer chemotherapy. The use of non-toxic prodrugs, or of liposome-encapsulated drugs, allows a better targeting of the tumours and may, therefore, improve the tolerance to the treatment. Using the model of isolated perfused rat heart, we have evaluated the cardiotoxicity of a novel prodrug of doxorubicin, HMR-1826, which consists of the association of doxorubicin to glucuronic acid. We have compared the cardiac effects (developed pressure, contractility and relaxation of the left ventricle) induced by HMR-1826 to those induced by doxorubicin and Doxil, a liposomal form of doxorubicin. HMR-1826 was administered intravenously every other day for 11 days at doses of 50–200 mg kg−1 per injection while doxorubicin was administered according to the same protocol at doses of 1–3 mg kg−1 per injection. Doxorubicin strongly decreased the cardiac functional parameters at the doses of 2.5 and 3 mg kg−1 per injection. Doxil (3 mg kg−1) and HMR-1826 (50–150 mg kg−1) were largely devoid of cardiotoxicity. HMR-1826 only induced significant alterations of the cardiac function at the highest dose used (200 mg kg−1 per injection). These alterations were much lower than those of doxorubicin at 2.5 mg kg−1 per injection, despite similar general toxicity symptoms (weight loss, nose bleeding and diarrhoea) at these respective doses. Thus, HMR-1826 appeared about 100-fold less cardiotoxic than doxorubicin. © 1999 Cancer Research Campaign
Keywords: cardiotoxicity, anthracyclines, prodrug therapy
Full Text
The Full Text of this article is available as a PDF (79.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baurain R., Deprez-De Campeneere D., Trouet A. Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. Anal Biochem. 1979 Apr 1;94(1):112–116. doi: 10.1016/0003-2697(79)90799-1. [DOI] [PubMed] [Google Scholar]
- Bosslet K., Straub R., Blumrich M., Czech J., Gerken M., Sperker B., Kroemer H. K., Gesson J. P., Koch M., Monneret C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998 Mar 15;58(6):1195–1201. [PubMed] [Google Scholar]
- Connors T. A., Whisson M. E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature. 1966 May 21;210(5038):866–867. doi: 10.1038/210866b0. [DOI] [PubMed] [Google Scholar]
- Florent J. C., Dong X., Gaudel G., Mitaku S., Monneret C., Gesson J. P., Jacquesy J. C., Mondon M., Renoux B., Andrianomenjanahary S. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem. 1998 Sep 10;41(19):3572–3581. doi: 10.1021/jm970589l. [DOI] [PubMed] [Google Scholar]
- Lorell B. H., Wexler L. F., Momomura S., Weinberg E., Apstein C. S. The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts. Circ Res. 1986 May;58(5):653–663. doi: 10.1161/01.res.58.5.653. [DOI] [PubMed] [Google Scholar]
- Mürdter T. E., Sperker B., Kivistö K. T., McClellan M., Fritz P., Friedel G., Linder A., Bosslet K., Toomes H., Dierkesmann R. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res. 1997 Jun 15;57(12):2440–2445. [PubMed] [Google Scholar]
- Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]